Background. In glioblastoma (GBM), the gene for epidermal growth factor receptor (EGFR) is frequently amplified. EGFR mutations also are common, including a truncation mutation that yields a constitutively active variant called EGFR variant (v)III. EGFRvIIIpositive GBM progresses rapidly; however, the reason for this is not clear because the activity of EGFRvIII is attenuated compared with EGF-ligated wild-type EGFR. We hypothesized that EGFRvIII-expressing GBM cells selectively express other oncogenic receptors that support tumor progression.
The goal of the present study was to determine whether RTKs are selectively overexpressed in EGFRvIII-positive GBM cells.
We began our research by mining transcriptome profiling data from The Cancer Genome Atlas (TCGA). Our analysis demonstrated a significant correlation between the level of expression of EGFR and vascular endothelial growth factor receptor 2 (VEGFR2/kinase insert domain receptor [KDR] ). We also determined that VEGFR2 is expressed at significantly higher levels in tumors that express EGFRvIII. Because TCGA data reflect total harvested RNA, we sought to confirm our findings using cell culture model systems and xenografts of human GBM in mice. VEGFR2 is expressed by endothelial cells and implicated in angiogenesis and vasculogenesis. 11, 12 Drugs targeting VEGF-VEGFR2 signaling have been used to treat a variety of cancers. 13, 14 GBM tumors are notable for intense microvascular proliferation, thought to reflect VEGF released by tumor cells acting through endothelial cell VEGFR2. 15 However, previous studies have shown that in addition to endothelial cells, neoplastic GBM cells also express VEGFR2. 16 -18 The results presented in this paper demonstrate that VEGFR2 expression is increased in GBM cells in which EGFR signaling is activated. In these cells, VEGFR2 inhibits cellular senescence and promotes cell cycle progression. Cellular senescence is usually considered an irreversible process in which cells enter cell cycle arrest at the G1/G0 phase. 19, 20 Molecular markers of senescence include the cyclin-dependent kinase inhibitors (CDKIs) p16
INK4a /CDKN2a, p21 Cip1a , and p27 Kip1 and hypophosphorylation of retinoblastoma protein (Rb). 19, 20 In premalignant conditions, senescence pathways may be activated to halt unrestricted cell growth. 21, 22 When senescence occurs within the context of cancer therapeutics, the response is termed therapy-induced senescence (TIS). 20 Although replicative arrest, which is characteristic of TIS, may be favorable in cancer treatment, the concomitant resistance to apoptosis may make absolute cancer eradication more difficult. The activity of VEGFR2 in preventing cellular senescence in GBM cells in which EGFR is activated may contribute to the aggressive nature of these tumor cells. We further propose that antiangiogenic drugs, which target VEGF signaling, may have a direct effect on GBM cells, inducing cellular senescence, in addition to the known effects on tumor vasculature.
Materials and Methods

Mining The Cancer Genome Atlas Data with cBioPortal
TCGA mRNA data were downloaded for a panel of GBM samples from the cBioPortal for Cancer Genomics including RNA-Seq Version 2 RSEM and Agilent microarray z-scores. 23 -25 EGFRvIIIpositive or -negative status was derived from the Nanostring nCounter platform. 26 Mean z-scores for EGFRvIII-negative and -positive tumors were compared by unpaired t-tests. Log2 RSEM values for EGFR were plotted against values for VEGFR2, stem cell growth factor receptor (SCGFR/c-Kit), platelet derived growth factor receptor (PDGFR)b, and hepatocyte growth factor receptor (HGFR/c-Met). Statistical analysis was performed to determine the Pearson correlation coefficient (r) and the corresponding P-value.
Immunohistochemistry
An EGFRvIII-expressing human GBM (GBM39) and an EGFRvIIInegative GBM in which wtEGFR was amplified (GBM8) were propagated as xenografts as previously described 10, 27 and kindly provided by C. David James (Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University). Harvested tumor tissue was formalin fixed and paraffin embedded for sectioning and immunohistochemistry (IHC) using an antibody against VEGFR2. Detailed IHC methods are listed in the Supplementary material.
Cell Lines
U87MG cells that express EGFRvIII or overexpress wtEGFR have been previously described, 5 as have U373MG cells that express EGFRvIII under the control of a doxycycline (Dox)-repressible promoter and U373MG cells that overexpress wtEGFR. 28 Detailed cell culture maintenance methods are listed in the Supplementary material.
Immunoblot Analysis
Immunoblot analysis was performed as previously described. 10 Detailed methods are listed in the Supplementary material.
Relative Real-time Quantitative PCR
Total RNA was isolated using the NucleoSpin RNA II Kit (MachereyNagel). Complementary DNA was synthesized with the iScript cDNA Synthesis Kit (Bio-Rad). Quantitative (q)PCR was carried out using TaqManFast Universal PCR Mastermix 2x, and TaqMan primers and probes. Detailed methods and descriptions of primers/probes are provided in the Supplementary material.
Small Interfering RNA Transfection
VEGFR2-specific ON-TARGETplus small interfering (si)RNA or ON-TARGETplus nontargeting control (NTC) siRNA was introduced into cells by incubation with Lipofectamine 2000 (Invitrogen). The extent of gene silencing was determined by qPCR and immunoblot analysis. Detailed sequences and methods are provided in the Supplementary material.
Bromodeoxyuridine Incorporation
Cell proliferation was measured by bromodeoxyuridine (BrdU) incorporation using a fluorescently conjugated BrdU-specific antibody as previously described. 10 Detailed methods are provided in the Supplementary material.
Cell Death Assay
Cell death was determined using the Cell Death Detection Enzyme-Linked Immunosorbent Assay (ELISA) Plus Kit (Roche Applied Science) according to the manufacturer's instructions. Cells were transfected with siRNA or treated with cediranib prior to performing the assay. Statistical significance was determined by an unpaired t-test. 
Senescence-associated b-galactosidase Staining
Results
EGFR and Receptor Tyrosine Kinase Coexpression in Human GBM
To compare gene expression in human GBM, we mined TCGA RNA-Seq and Agilent microarray transcriptome profiling data. Tumors were classified as EGFRvIII positive or negative based on Nanostring nCounter analyses. 26 Figure 1A shows that EGFR expression was significantly increased in tumors that were EGFRvIII positive, as anticipated (P , .001). The z-score, shown in Fig. 1A , reports gene expression as the number of standard deviations displaced from a mean value, determined using a reference group of TCGA tumors. These results support the conclusion that EGFRvIII occurs in the context of EGFR gene amplification or overexpression. 4, 26 Next, we mined RNA-Seq data to determine whether there is a correlation between expression of EGFR and other RTKs implicated in GBM progression. 18, 29, 30 Of the RTKs examined, VEGFR2 showed the strongest positive correlation (Fig. 1B) . Although the Pearson correlation coefficient was only 0.26, the correlation was statistically significant (P , .01). Additional RTKs Fig. S1C ).
Next we examined VEGFR2 expression in EGFRvIII-positive vs -negative GBM and showed that VEGFR2 was significantly increased in EGFRvIII-positive tumors (P , .01) (Fig. 1C) . Given the nature of TCGA transcriptome profiling data, the source of VEGFR2 (tumor cells vs nonmalignant cells, such as endothelium) could not be determined. To further examine the relationship between EGFR and VEGFR2 in human samples, we compared 2 previously characterized human GBM tumors that had been propagated as xenografts and shown to retain the original molecular characteristics of the parent tumors. 27, 31 IHC studies were performed to detect VEGFR2. As shown in Fig. 1D (top panels), VEGFR2 was not detected in tumor cells in EGFRvIII-negative GBM (GBM8), in which EGFR was amplified. Blood vessels provided an internal VEGFR2-positive control (arrows). By contrast, in EGFRvIII-positive GBM (GBM39), the tumor cells were robustly immunopositive for VEGFR2. Again, arrows in Fig. 1D point to blood vessels, which provided an internal positive control.
VEGFR2 Expression in EGFRvIII-positive GBM Cell Lines
To test whether EGFR induces VEGFR2 expression in GBM cells, first we studied the U87MG GBM model system. 5 Cells that express EGFRvIII or overexpress wtEGFR and parental U87MG cells were compared. Figure 2A shows that the total level of EGFR was similar in cells that express EGFRvIII or overexpress wtEGFR. The lower molecular mass of EGFRvIII is due to truncation of exons 2 -7.
4,5 EGFR was detected in parental cells only when immunoblots were exposed for longer periods of time (results not shown). Tyr-1068 in EGFR was phosphorylated in EGFRvIII-expressing cells, reflecting the constitutive activity of this mutant. 4, 5 Low levels of phospho-Tyr-1068 in wtEGFRoverexpressing cells may reflect endogenously produced ligands or ligand-independent signaling. 32 Extracellular signalregulated kinase (ERK)1/2, a well-defined downstream target of EGFR, was phosphorylated to a greater extent in EGFRvIIIexpressing U87MG cells, as anticipated. EGFR mRNA was increased similarly in U87MG cells that expressed EGFRvIII or overexpressed wtEGFR, confirming the results of our immunoblotting studies (Fig. 2B) .
VEGFR2 protein was increased .3-fold (n ¼ 3) in EGFRvIIIexpressing U87MG cells, compared with wtEGFR-overexpressing U87MG cells or parental cells, as determined by immunoblot analysis and densitometry (Fig. 2C) . To confirm the specificity of our antibody, we silenced VEGFR2 gene expression using siRNA in EGFRvIII-positive cells. Figure 2D shows that the 230-kDa band, corresponding to VEGFR2, was nearly completely eliminated by VEGFR2 gene silencing. Phospho-ERK1/2 was unchanged by VEGFR2 gene silencing, confirming the dominant activity of EGFRvIII in controlling this signaling factor.
VEGFR2 mRNA was increased more than 10-fold in EGFRvIIIexpressing U87MG cells compared with parental and wtEGFRoverexpressing cells, as determined by qPCR (Fig. 2E) . Because PDGFRb expression correlated with EGFR expression in our TCGA analysis, we examined PDGFRb by immunoblot analysis in the U87MG model system. Figure 2F shows that neither overexpression of wtEGFR nor EGFRvIII induced expression of PDGFRb in U87MG cells. In fact, PDGFRb was decreased in cells that expressed either form of EGFR.
As a second GBM model system, we studied U373MG cells in which wtEGFR was overexpressed or EGFRvIII was expressed downstream of a Dox-repressible promoter.
28 Figure 3A compares total EGFR protein expression. The U373MG cells that carry the regulated EGFRvIII promoter system were cultured in the presence or absence of Dox for 4 days to control EGFRvIII expression. Dox dramatically reduced EGFRvIII expression, as determined by immunoblot analysis, confirming the effectiveness of the promoter system. By qPCR, Dox treatment decreased EGFRvIII mRNA by about 80% (P , .001) (Fig. 3B) .
VEGFR2 protein was increased .4-fold in U373MG cells in which EGFRvIII was expressed compared with wtEGFRoverexpressing cells (Fig. 3C ). When EGFRvIII-expressing cells were treated with Dox, VEGFR2 protein expression was decreased (Fig. 3C) . Dox also significantly decreased expression of VEGFR2 mRNA (P , .001), as determined by qPCR (Fig. 3D) . Figure 3E shows that VEGFR2 gene silencing nearly completely blocked detection of VEGFR2 in U373MG cells, once again confirming the specificity of our immunoblotting system. Although EGFRvIII significantly increased VEGFR2 expression in EGFRvIIIexpressing U87MG cells and U373MG cells, the amount of VEGFR2 detected in these cells was still lower than that detected in extracts of human umbilical vein endothelial cells, which are frequently examined as a positive control for this RTK (Supplementary Fig. S2 ). The VEGFR2 detected in GBM cells did not reflect contamination by endothelial cells, since Tie2 was not observed in GBM cell extracts.
VEGFR2 Expression in GBM Cells Is Regulated by EGFR Signaling
We hypothesized that VEGFR2 expression is increased in GBM cells as a consequence of activated EGFR signaling. To test this hypothesis, we treated wtEGFR-overexpressing U87MG cells with EGF (10 ng/mL). VEGFR2 protein levels were increased, as determined by immunoblot analysis (Fig. 4A) . VEGFR2 mRNA was increased as well (P , .05) (Fig. 4B) . EGF treatment also increased VEGFR2 protein (Fig. 4C) and mRNA (Fig. 4D ) in wtEGFR-overexpressing U373MG cells. The EGFinduced increase in VEGFR2 was partially blocked by the mitogen/ERK (MEK) inhibitor PD98059 and by the nuclear factor -kappaB (NFkB) nuclear translocation inhibitor JSH-23.
Similar results were obtained when we studied EGFRvIIIexpressing cells in the absence of EGF supplementation. JSH-23 and PD98059 significantly decreased VEGFR2 protein levels (Fig. 4E ) and VEGFR2 mRNA levels (Fig. 4F) in EGFRvIIIexpressing U373MG cells. Both ERK1/2 and NFkB are reported to be activated downstream of EGFRvIII.
10,33
VEGFR2 Prevents Cellular Senescence in EGFRvIII-expressing GBM Cells
To determine whether VEGFR2 regulates growth or survival of GBM cells, we silenced the VEGFR2 gene in EGFRvIII-expressing Jones et al.: VEGFR2 prevents senescence in glioblastoma cells U373MG cells. Control cells were transfected with NTC siRNA. BrdU incorporation was studied as an index of DNA synthesis and cell cycle progression. Figure 5A and B show that VEGFR2 gene silencing significantly decreases BrdU incorporation. VEGFR2 gene silencing did not increase apoptosis, as determined by measuring cleaved poly(ADP-ribose) polymerase (PARP) and activated/cleaved caspase-3 (Fig. 5C ). We also probed for an increase in apoptosis using the Roche Cell Death ELISA Kit, which measures intracytoplasmic histoneassociated DNA fragments. Figure 5D shows that silencing of VEGFR2 did not have an effect on cell death.
Next, we stained cells to detect SA-b-Gal, a well-accepted biomarker of cellular senescence. Figure 5E shows representative images of EGFRvIII-expressing U373MG cells transfected with NTC or VEGFR2-specific siRNA. As shown in Fig. 5F , VEGFR2 gene silencing induced a 4-to 5-fold increase in cells Fig. 2 . VEGFR2 is increased in EGFRvIII-expressing U87MG GBM cells. (A) Cell extracts from parental, wtEGFR-overexpressing, and EGFRvIII-expressing U87MG cells were subjected to immunoblot analysis using the indicated antibodies. Blots were immunostained to detect tubulin as a loading control. (B) Total EGFR mRNA (wtEGFR + EGFRvIII) was determined by qPCR and standardized against the level present in parental cells (mean+SEM, n ¼ 3). (C) Immunoblot analysis to detect VEGFR2 was performed comparing parental, wtEGFR-overexpressing, and EGFRvIII-expressing U87MG cells. Each cell type is shown in duplicate. VEGFR2 signal intensity was standardized against actin and shown relative to that measured in parental cells (n ¼ 3). (D) EGFRvIII-expressing U87MG cells were transfected with VEGFR2-specific (+) or NTC siRNA (2) for 24 h and subjected to immunoblot analysis to detect VEGFR2, phosphorylated ERK1/2 (P-ERK1/2), and total ERK1/2. (E) VEGFR2 mRNA was determined by qPCR and standardized against levels present in parental cells (mean+SEM, n ¼ 3, *P , .05). (F) Immunoblot analysis to detect PDGFRb was performed comparing parental, wtEGFR-overexpressing, and EGFRvIII-expressing U87MG cells (in duplicate).
positive for SA-b-Gal (P , .001). Induction of senescence provides a plausible explanation for the decrease in DNA synthesis in VEGFR2 gene-silenced EGFRvIII-expressing U373MG cells.
VEGFR-specific Tyrosine Kinase Inhibition Induces Senescence in EGFRvIII-positive GBM Cells
To further explore the role of VEGFR2 in preventing cellular senescence in GBM cells, we studied the VEGFR-specific tyrosine kinase inhibitor cediranib (AZD2171), which has been used to treat GBM in patients. 34 Under basal cell culture conditions, VEGFR2 was at least partially activated in EGFRvIII-expressing U373MG cells, as determined by immunoblotting for VEGFR2 phospho-Tyr-1059 (Fig. 6A) . Treating the cells with 5 mM cediranib for 24 h substantially decreased phospho-Tyr-1059.
Cediranib inhibited DNA synthesis and cell cycle progression in EGFRvIII-expressing U373MG cells, as determined by BrdU incorporation (Fig. 6B and C) (P , .001) . Cleaved PARP was not increased in cediranib-treated cells, once again providing evidence that neutralizing VEGFR2 does not promote GBM cell apoptosis (Fig. 6D) . Cediranib did not effect EGFRvIII phosphorylation at Tyr-1068. By contrast, cediranib increased the percentage of SA-b-Gal-staining cells, as shown in representative images (Fig. 6E ) and in summary form in Fig. 6F (P , .001) . Addition of EGF did not significantly offset the effects of cediranib on induction of senescence as determined by SA-b-Gal staining.
Our cediranib and VEGFR2 gene-silencing studies suggested that neutralizing VEGFR2 activity in EGFRvIII-expressing GBM cells may induce cellular senescence. To further test this hypothesis, we examined phosphorylation of Rb protein at Ser-807/811, which is known to promote transition into S phase. 35 Phospho-Ser-807/811 was decreased in cediranibtreated cells (Fig. 6G) , supporting the hypothesis that this drug induces cellular senescence. We also observed an increase in p27 Kip1 , a CDKI expressed at increased levels in senescent cells. 
001). (E)
EGFRvIII-expressing U373MG cells were transfected with VEGFR2-specific or NTC siRNA for 24 h and subjected to immunoblot analysis to detect VEGFR2. Fig. 4 . EGFR signaling to MEK and NFkB controls VEGFR2 expression in GBM cells. (A) Parental, wtEGFR-overexpressing, and EGFRvIII-expressing U87MG cells were serum starved for 18 h and then incubated with EGF (10 ng/mL) (+) or vehicle (2) for 6 h. Immunoblotting was performed to detect VEGFR2. (B) VEGFR2 mRNA levels were determined in wtEGFR-overexpressing U87MG cells treated with EGF (+) or vehicle (2) by qPCR and standardized against vehicle-treated cells (mean+SEM, n ¼ 3, *P , .05). (C) WtEGFR-overexpressing U373MG cells were serum starved for 18 h and then pretreated for 15 min with either JSH-23 (10 mM), PD98059 (50 mM), or vehicle (dimethyl sulfoxide [DMSO] ). The cells were subsequently treated with EGF (10 ng/mL) (+) or vehicle (2) for 6 h. Immunoblot analysis was performed to detect EGFR and VEGFR2. T-EGFR ¼ Total not truncated EGFR. (D) WtEGFR-overexpressing U373MG cells were serum starved for 18 h and pretreated for 15 min with either JSH-23 (10 mM), PD98059 (50 mM), or vehicle and then treated with EGF (10 ng/mL) (+) or vehicle (2) for 6 h. VEGFR2 mRNA was determined by qPCR (mean+SEM, n ¼ 4, ***P , .001). (E) EGFRvIII-expressing U373MG cells were serum starved for 18 h and treated with either JSH-23 (10 mM), PD98059 (50 mM), or vehicle for 6 h. Immunoblot analysis was performed to detect VEGFR2, phospho-ERK1/2 (P-ERK1/2), and tubulin as a control for load. (F) EGFRvIII-expressing U373MG cells were serum starved for 18 h and treated with either JSH-23 (10 mM), PD98059 (50 mM), or vehicle (DMSO) for 6 h. VEGFR2 mRNA was determined by qPCR and standardized against the level present in vehicle-treated cells (mean+SEM, n ¼ 5, **P , .01).
Jones et al.: VEGFR2 prevents senescence in glioblastoma cells
Discussion
EGFR gene amplification and EGFRvIII are known drivers of an aggressive phenotype in GBM. 2, 5, 7 We have demonstrated that tumor cells with activated EGFR signaling express increased levels of VEGFR2. The increase in VEGFR2 expression potentiates this RTK as a regulator of GBM cell physiology. Our results suggest that VEGFR2 synergizes with activated EGFR to promote cell cycle progression and avoid cellular senescence in GBM EGFRvIII-expressing U373MG cells were transfected with VEGFR2-specific or NTC siRNA. Cell death was determined using the Cell Death Detection ELISA Plus Kit (mean+SEM, n ¼ 6, n.s., not statistically significant). (E) EGFRvIII-expressing U373MG cells were transfected with VEGFR2-specific or NTC siRNA. Senescence was determined by SA-b-Gal staining (blue). Cells were imaged by brightfield microscopy. Representative fields are shown. (F) The number of SA-b-Gal-positive cells after transfection with VEGFR2-specific or NTC siRNA was determined using ImageJ and normalized against that observed in cultures of NTC siRNA-transfected cells (mean+SEM, n ¼ 4, ***P , .001).
cells. When VEGFR2 is silenced, a significant fraction of the GBM cells become senescent. Similarly, targeting VEGFR2 with the specific tyrosine kinase inhibitor cediranib induces cellular senescence that cannot be rescued with exogenous EGF. The function of VEGFR2 in EGFRvIII-expressing GBM cells may help explain the aggressive nature of these cells despite the fact that the tyrosine kinase activity of EGFRvIII is attenuated compared with EGF-ligated wtEGFR. 6 In clinical trials, cediranib has demonstrated efficacy in patients with recurrent GBM by decreasing overall tumor burden, normalizing tumor vasculature, decreasing vasogenic edema, and improving cerebral perfusion. 36, 37 An increase in overall Jones et al.: VEGFR2 prevents senescence in glioblastoma cells survival also has been observed. Serial MR spectroscopy studies demonstrated that cediranib has a direct effect on GBM cells by increasing the N-acetylaspertase to choline ratio, a biomarker of decreased cellular metabolism. 38 These changes are consistent with cediranib causing TIS in GBM cells, as described here, in addition to its effects on tumor vasculature. Cellular senescence occurs secondary to different stimuli, including dysfunctional telomeres, DNA damage, chromatin alterations, and generalized cell stress. 19 Cell-signaling proteins implicated in cellular senescence include p53, Rb, and the CDKIs p16
Ink4a , p21 Cip1a , and p27 Kip1 . Cellular pathways that induce senescence are thought to be activated in premalignant conditions, such as colonic adenoma. 21, 22 In these lesions, overriding senescence may be essential for malignant transformation. 21, 22 TIS is a form of cellular senescence induced in cancer cells by cytotoxic and targeted drug therapies. 20, 21 Previous studies have suggested that targeting VEGF signaling may induce TIS in colon cancer cells 39 and renal cell carcinoma cells. 40 In our GBM model system, evidence that cediranib induced TIS included increased SA-b-Gal staining, increased p27
Kip protein expression, and decreased phosphorylation of Rb at Ser-807 and 811. We also observed a significant decrease in DNA synthesis, as determined by BrdU labeling, in the absence of apoptosis. Because we conducted experiments with homogeneous cell culture model systems, we can be certain that the effects of cediranib were due to direct interactions with the GBM cells and not an indirect consequence of targeting endothelial cells. Evidence for decreased proliferation and cellular senescence was also obtained when the VEGFR2 gene was silenced. These results suggest that in GBM receiving VEGFR2-directed chemotherapy, the cancer cells may be targets, in addition to endothelial cells.
The assumption that cellular senescence is associated with irreversible replicative arrest and resistance to apoptosis is important in the context of this study and TIS in general. The enhanced ability of senescent cancer cells to survive is evident when these cells are subjected to radiation or chemotherapy drugs in the alkylating agent family, which target dividing cells. 20, 22 Such therapies are commonly utilized in treating GBM and may be used in conjunction with VEGFR-targeting drugs. 41 Our studies suggest that by inducing senescence, VEGFR-targeting drugs may inhibit the response to cytotoxic therapies. Testing this hypothesis is an important future goal. If TIS secondary to VEGFR-targeting drugs permits survival of cancer cells that would have otherwise been killed by cytotoxic therapies, then the irreversible nature of replicative arrest becomes increasingly critical. Gene products such as urokinasetype plasminogen activator and its receptor, uPAR, have been implicated in the release of tumor cells from states of replicative dormancy. 42 Their function in TIS induced by VEGFRtargeting drugs remains to be determined.
Our decision to focus on the activity of VEGFR2 in EGFRvIIIexpressing GBM cells was based on an analysis of TCGA data. We confirmed that VEGFR2 is upregulated downstream of EGFRvIII in multiple model systems, including a human GBM xenograft model. 27 Our hypothesis that VEGFR2 is upregulated in EGFRvIII-expressing cells due to activation of EGFR-dependent cell signaling was supported by studies with pharmacologic inhibitors of the MEK-ERK1/2 pathway and NFkB signaling. In addition, we showed that treating wtEGFR-overexpressing GBM cells with EGF upregulates VEGFR2 expression. These results suggest that VEGFR2 expression in vivo may be controlled not only by EGFRvIII but also by wtEGFR, when EGF is abundant in the tumor microenvironment.
The cytoplasmic tail of VEGFR2 includes multiple Tyr residues that are phosphorylated upon receptor activation and serve as docking sites for cell-signaling proteins implicated in cell cycle progression, including phosphatidylinositol-3 kinase, 43 protein tyrosine kinase 2 /focal adhesion kinase 1, 44 mesenchymal epithelial transition factor, 45 Src family kinases, 46 phospholipaseC1g, 47 and Cdc42. 48 Some of these cell-signaling proteins are activated downstream of EGFR as well. The cell-signaling factors activated selectively downstream of VEGFR2 to inhibit induction of cellular senescence in GBM cells remain to be determined. These signaling factors may also be candidate targets for inducing senescence as an approach to treating cancer.
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